Shattuck Labs, Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 76.17K shares.
- Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 38.00K shares.
- Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 0.00 shares.
- Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 0.00 shares, a 100.00% decline year-over-year.
- Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 0.00 shares, a 100.00% decline from fiscal 2024.
- Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 318.76K shares, a 135.67% increase from fiscal 2023.
- Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 135.25K shares, a 250.40% increase from fiscal 2022.
- Shattuck Labs, Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 38.60K shares, a 93.08% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 76.17K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-11 | 114.17K shares derived: sum of 4 quarters · filed 2026-08-11 |
| 2026-03-31 | 38.00K shares 10-Q · filed 2026-05-07 | 38.00K shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-05 | 0.00 shares 10-K · filed 2026-03-05 |
| 2025-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | -25.00K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-14 | -24.84K shares derived: sum of 4 quarters · filed 2025-08-14 |
| 2025-03-31 | 0.00 shares 10-Q · filed 2025-05-01 | 180.20K shares derived: sum of 4 quarters · filed 2025-05-01 |
| 2024-12-31 | -25.00K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-27 | 318.76K shares 10-K · filed 2025-03-27 |
| 2024-09-30 | 162.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-14 | 467.22K shares derived: sum of 4 quarters · filed 2024-11-14 |
| 2024-06-30 | 205.04K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 467.06K shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 138.56K shares 10-Q · filed 2024-05-02 | 273.09K shares derived: sum of 4 quarters · filed 2024-05-02 |
| 2023-12-31 | 123.46K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-29 | 135.25K shares 10-K · filed 2024-02-29 |
| 2023-09-30 | 0.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-09 | 11.79K shares derived: sum of 4 quarters · filed 2023-11-09 |
| 2023-06-30 | 11.08K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-10 | 12.51K shares derived: sum of 4 quarters · filed 2023-08-10 |
| 2023-03-31 | 717.00 shares 10-Q · filed 2023-05-09 | 4.93K shares derived: sum of 4 quarters · filed 2023-05-09 |
| 2022-12-31 | 0.00 shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-23 | 38.60K shares 10-K · filed 2023-02-23 |
| 2022-09-30 | 712.00 shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-09 | 135.52K shares derived: sum of 4 quarters · filed 2022-11-09 |
| 2022-06-30 | 3.50K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-11 | 257.61K shares derived: sum of 4 quarters · filed 2022-08-11 |
| 2022-03-31 | 34.39K shares 10-Q · filed 2022-05-12 | 578.46K shares derived: sum of 4 quarters · filed 2022-05-12 |
| 2021-12-31 | 96.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-03-15 | 557.61K shares 10-K · filed 2022-03-15 |
| 2021-09-30 | 122.81K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-09 | 478.85K shares derived: sum of 4 quarters · filed 2021-11-09 |
| 2021-06-30 | 324.34K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-12 | |
| 2021-03-31 | 13.54K shares 10-Q · filed 2021-05-10 | |
| 2020-12-31 | 18.16K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-03-16 | 181.45K shares 10-K · filed 2021-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Neurogene Inc. (NGNE) | $0.625B | -4.46 | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| IMPACT BIOMEDICAL INC. (IBO) | United States | $0.611B | 66.47 |
| Aquestive Therapeutics, Inc. (AQST) | United States | $0.606B | -6.67 |
| CorMedix Inc. (CRMD) | United States | $0.605B | 3.25 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| CytomX Therapeutics, Inc. (CTMX) | United States | $0.598B | -10.25 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |